Eli Lilly and Company (NYSE:LLY) Connects Clinical Research With Expanding Medicine Sales

Aditi Sarkar

27 October 2026 05:37 PM AEDT

Eli Lilly and Company (NYSE:LLY) Connects Clinical Research With Expanding Medicine Sales

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Lilly's October clinical update explores immune and metabolic responses in adults receiving a combination of psoriasis and obesity medicines.
Worldwide medicine volumes increased 60% in the June quarter, outweighing lower realised prices and supporting higher reported revenue growth.
The company's revised annual outlook includes higher revenue expectations alongside substantial spending on research and acquired development programmes during FY26.
Directors declared a quarterly dividend of USD 1.73 per share on 26 October while the company's clinical programmes continued.

Research into interconnected diseases is expanding alongside commercial growth at Eli Lilly and Company (NYSE:LLY). An October analysis of its psoriasis and obesity medicines examined biological changes in patients receiving combination treatment, adding to a wider clinical programme funded by a growing medicine business. Lilly shares closed at USD 1,279.14, up 0.45%, after the market session ended on 26 October 2026. A dividend declaration that day added another capital allocation update, while management's August annual guidance remained the financial outlook available at the closing date.

Combination Study Examines Immune and Metabolic Biology

The 9 October update concerned TOGETHER-PsO, a Phase 3b trial comparing Taltz plus Zepbound with Taltz alone. The study enrolled adults with moderate-to-severe plaque psoriasis and obesity, or overweight accompanied by another weight-related condition.

A prespecified exploratory analysis assessed circulating proteins and gene expression in blood. At Week 36, combination treatment was associated with changes in more measured proteins and genes than Taltz monotherapy. The work investigated links between immune and metabolic processes rather than establishing a new treatment approval.

The randomised study included 274 participants over 52 weeks. Earlier clinical results showed greater skin clearance and weight reduction with the combination, with improvements maintained or extended through Week 52. The safety findings remained consistent with the known profiles of the two medicines.

These different measures serve different purposes within the trial. Clinical outcomes assess effects on patients, while the biomarker analysis explores the biology accompanying treatment. The October findings add detail to that research programme without changing the exploratory status of the analysis.

Higher Volumes Support Revenue Despite Pricing Pressure

For 2QFY26, revenue increased 48% YoY to USD 23.0bn. A 60% increase in worldwide volumes more than offset a 13% decline in realised prices. Mounjaro and Zepbound were the principal revenue drivers, and international operations recorded faster percentage growth than the United States.

Reported earnings rose 26% YoY to USD 7.94 per share. Research and development expenditure reached USD 3.8bn, increasing 14%, while acquired in-process research and development charges were approximately USD 2.8bn.

The acquired development charges affected reported and non-GAAP earnings. Lilly's earnings performance therefore reflected expansion in medicine sales together with investment and charges associated with the development portfolio.

Annual Guidance Retains Development Spending and Portfolio Priorities

The August update raised FY26 revenue guidance to USD 85bn–87bn. Non-GAAP earnings guidance increased to USD 35.50–36.50 per share, including the impact of acquired development charges. These ranges remain management's expectations for the year.

On 26 October, the board declared a fourth-quarter dividend of USD 1.73 per share. That distribution sits alongside investment in a business spanning diabetes, obesity, immune disorders, oncology and neuroscience.

Lilly's stated research approach includes biotechnology, chemistry and genetic medicine. It continues to evaluate new medicines and additional settings for existing treatments. The latest psoriasis analysis is one part of that effort, with its study design and exploratory endpoints distinct from the company's annual commercial forecasts. Further clinical work and execution of the operating plan remain parallel priorities across the portfolio.

FAQs

Q: Which Treatments Were Evaluated Together?

A: TOGETHER-PsO evaluated Taltz with Zepbound against Taltz alone.

Q: What Drove June-Quarter Revenue Growth?

A: Higher medicine volumes outweighed lower realised prices.

Q: What Annual Revenue Range Did Lilly Forecast?

A: The August guidance was USD 85bn–87bn for FY26.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.